Current Understanding and Management of Giant Cell Arteritis and Polymyalgia Rheumatica Parasar Ghosh; Frances A Borg; Bhaskar Dasgupta Disclosures Expert Rev Clin Immunol. 2010;6 (6):913-928. 0 ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell arteritis (GCA), or temporal arteritis, an autoimmune disease of medium ...

Giant cell arteritis (GCA), also known as temporal arteritis, is an autoimmune disease of medium and large arteries, characterized by granulomatous inflammation of the three-layered vessel wall ...

Giant cell arteritis (GCA), also known as temporal arteritis, is an autoimmune disease of medium and large arteries, characterized by granulomatous inflammation of the three-layered vessel wall, which ...

The Food and Drug Administration (FDA) has approved Rinvoq ® (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA). The approval was based on ...

Avtozma (tocilizumab-anoh) is a newly approved biosimilar to Actemra (tocilizumab), developed by Celltrion. It is designed to treat several autoimmune and inflammatory conditions, including rheumatoid ...

SEASIDE, Calif. — Several juvenile detention centers on the Central Coast have introduced a virtual reality program, focused on marine science. The immersive experience will allow incarcerated ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck.

Finally, juvenile temporal arteritis occurs in boys and young men regardless of ethnic background, and the prominent histological features occurring in all vessels are vascular proliferation, ...

All diagnoses of giant cell arteritis made through temporal artery ultrasound were unchanged at 1 month — and at 2 years, for those with available data — in a study published in Annals of ...

Juvenile osteochondritis is a condition mainly affecting children 10–15 years old who are physically active. It causes symptoms like pain, swelling, and reduced mobility.